Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-08-24 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司及子公司为子公司融资提供反担保的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from a sponsoring institution regarding a guarantee provided by a company and its subsidiary for financing purposes. It references regulatory rules related to securities issuance and listing, and details the approval process and the guarantee's impact on the company. The document is short (1033 characters) and focuses on a specific financing guarantee matter rather than presenting financial statements or comprehensive financial data. It is not an annual or interim report, nor an earnings release or management discussion. It is also not a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities and guarantees related to loans for a subsidiary.
2023-08-24 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2023 to June 30, 2023. It contains detailed financial data including income, expenses, assets, liabilities, and operational highlights. The document includes comprehensive financial statements, management discussion of business activities, risk factors, and other substantive financial and operational information typical of an interim or quarterly report. It is not a brief announcement or a certification letter, nor is it a full annual report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-17 Chinese
第六届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Beijing Northland Biotech Co., Ltd. It details the meeting date, attendance, and the approval of the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual 2023 semi-annual report and the special report as being published separately on the Beijing Stock Exchange website, indicating this document is a meeting resolution and announcement rather than the full semi-annual report itself. The document length is short (1410 characters), and it serves to announce the supervisory board's review and approval of these reports, not to present the financial data or detailed analysis. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-08-17 Chinese
独立董事关于第六届董事会第四次会议相关事项的独立意见公告
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on the company's sixth board meeting, specifically regarding the special report on the storage and use of raised funds for the half-year 2023 period. It reviews compliance with laws and company rules about fundraising usage. The document is a formal opinion related to a board meeting and fundraising usage, not a full financial report or audit. It is not an announcement of voting results or a general regulatory filing. The content aligns with a Capital/Financing Update (CAP) as it discusses fundraising and capital usage compliance.
2023-08-17 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" or "Interim Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the reporting period. The document also includes management assurances about the accuracy of the report and mentions that the report is unaudited. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). The document length is over 5,000 characters and contains substantive financial data, so it is not a mere announcement or certification. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2023
2023-08-17 Chinese
第六届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth board of directors' fourth meeting of Beijing Northland Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and the approval of the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and the special report but does not contain the full financial statements or substantive financial data itself. It is a board meeting resolution announcement rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2023-08-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.